Dana-Farber study: Cancer vaccine shows promise for patients with stage III and IV kidney cancer (IMAGE)
Caption
All nine patients treated at Dana-Farber Cancer Institute in a phase 1 trial of a personalized cancer vaccine for patients with stage III or IV kidney cancer with a high risk of recurrence, generated a successful anti-cancer immune response.
Credit
Dana-Farber Cancer Institute
Usage Restrictions
Kindly credit Dana-Farber Cancer Institute
License
Original content